Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Stephanie Mendez, J. Daniel Cuevas, Gabrielle B. Rocque, Joanne L. Blum, Jennifer M. Specht, Steven W. Corso, Yao Wang, Joseph C. Cappelleri, Jawad E Francis, Debu Tripathy, Veneta Pope
Publikováno v:
Cancer Research. 81:SS2-10
Background: The COVID-19 pandemic is negatively affecting patient enrollment, therapy administration, and patient visits in breast cancer clinical trials worldwide. COVID-19 may have a lasting impact on how clinical trials are conducted, and guidelin
Autor:
Akshara Singareeka Raghavendra, Katherine Clifton, Min Yi, Debu Tripathy, Jennifer K. Litton, Meghan Sri Karuturi
Publikováno v:
Cancer Research. 80:P5-11
Background: CDK 4/6 inhibitors have become frontline treatment for patients (pts) with advanced hormone receptor (HR) positive breast cancer. There is limited data regarding post-progression outcomes in pts receiving CDK 4/6 inhibitors as standard of
Autor:
Jennifer K. Litton, NT Ueno, V. Valero, Debu Tripathy, Senthil Damodaran, Richard B. Lanman, Victoria M. Raymond, S. L. Moulder, I. I. Wistuba, Stanley R. Hamilton, KR Hess, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 79:OT1-03
Background Mutations in the ligand-binding domain of ESR1 have been demonstrated to mediate resistance to aromatase inhibitors (AI) and are associated with poor survival. Analyses of circulating tumor DNA (ctDNA) offer a minimally invasive and real-t
Autor:
Debu Tripathy, Matthew P. Goetz, Daniel F. Hayes, Matthew J. Ellis, Melody A. Cobleigh, Ron Bose, Carey K. Anders, Michael Naughton, Shana Thomas, Eric P. Winer, Alshad S. Lalani, Jill Anderson, Melinda L. Telli, Rachel A. Freedman, Cynthia X. Ma, Gretchen Kimmick, P. Bedard, Richard B. Lanman, Timothy J. Pluard, Christy A. Russell, Kimberly L. Blackwell, Feng Gao, Caroline Bumb, Andres Forero, John D. Pfeifer, Mark D. Pegram, Kimberly C. Banks, Richard Bryce, Polly A. Niravath, Hussam Al-Kateb
Publikováno v:
Clinical Cancer Research. 23:5687-5695
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified me
Autor:
Debu Tripathy, Sabine Seiler, Lisa A. Carey, Ian E. Krop, Matthew P. Goetz, S Delalogue, Sherene Loi, E.M. Ciruelos, AM DeMichele, Aleix Prat, Sumithra J. Mandrekar, Kathy D. Miller, Luca Gianni, Elgene Lim, Ines Vaz-Luis, Otto Metzger, PA Francis, S. Loibl, Pinuccia Valagussa, C-S Huang, EP Winer, T Dockter, Christoph Mundhenke, J Lanzillotti
Publikováno v:
Cancer Research. 78:OT3-05
Background Pre-clinical data and initial results from clinical studies point to the added benefit of CDK4/6 inhibition when combined with anti-HER2 tx. The current study is designed to evaluate the added benefit of palbociclib when given in combinati
Autor:
Melody A. Cobleigh, Ginny Mason, Mary S. Beattie, Peter A. Kaufman, Adam Brufsky, Musa Mayer, Debu Tripathy, D. A. Yardley, Mohammad Jahanzeb, Bongin Yoo, S Hurvitz, Sandra M. Swain, HS Rugo, S Ogale, Joyce A. O'Shaughnessy
Publikováno v:
Cancer Research. 76:P6-17
Introduction HER2+ MBC patients with CNS metastases are often excluded from clinical trials. The Systemic Therapies for HER2+ Metastatic Breast Cancer Registry (SystHERs), a real-world, prospective registry study, is uniquely positioned to evaluate t
Autor:
Debu Tripathy, NT Ueno, V. Valero, Nuhad K. Ibrahim, Helen Piwnica-Worms, Jennifer K. Litton, Fraser Symmans, Wei Tse Yang, K. K. Hunt, Funda Meric-Bernstam, Banu Arun, Ravi Murthy, Elizabeth A. Mittendorf, Zahi Mitri, Stacy Moulder-Thompson, Alastair M. Thompson
Publikováno v:
Cancer Research. 76:OT2-03
BACKGROUND: In triple negative breast cancer (TNBC), pathologic compete response/residual cancer burden-0 (pCR/RCB-0) or minimal residual disease (RCB-I) following neoadjuvant chemotherapy (NACT) is associated with a good prognosis. This is in contra
Autor:
Debu Tripathy, Julie R. Gralow, Daniel F. Hayes, Anne F. Schott, James W. Hicks, William E. Barlow, Peter Kuhn, George Somlo, Gabriel Hortobagyl, Halle C. F. Moore, Danika Lew
Publikováno v:
Cancer Research. 75:OT2-1
BACKGROUND: The median survival for women with hormone-receptor-positive (HR+) stage IV metastatic breast cancer (MBC) is 36 months. Strategies to improve outcome for postmenopausal women, include combinations of aromatase inhibitors (AIs) with eithe
Autor:
Debu Tripathy, Joe Ensor, Rosalind P. Candelaria, Jennifer K. Litton, Kelly K. Hunt, Naoto T. Ueno, Ricardo H. Alvarez, Nuhad K. Ibrahim, Funda Meric-Bernstam, Fraser Symmans, Beth A Mittendorf, Banu Arun, Wei Yang, Rashmi Krishna Murthy, Helen Piwnica-Worms, Stacy Moulder-Thompson, Vicente Valero
Publikováno v:
Cancer Research. 75:OT3-2
BACKGROUND: Known disparities exist in patients with TNBC treated using neoadjuvant chemotherapy (NACT) with 30-50% having excellent response to treatment (pCR/RCB-I) and good survival prognosis, while 50-70% demonstrate marked residual disease (RCB-
Autor:
Debu Tripathy
Publikováno v:
Cancer Research. 70:ES9-2
Botanical agents have been used for centuries based on empiric observations of salutary effects on a variety of illnesses. A significant portion of our modern pharmacopeia is derived from botanical products and may be attributable to bioactive compon